Focused Ultrasound Matches Prostatectomy for Intermediate-Risk Prostate Cancer
LAS VEGAS — Focused ultrasound ablation for prostate cancer proved at least equivalent to radical prostatectomy for failure-free survival, according to a randomized trial reported here. After 3 years of follow-up, treatment failure had occurred in 5.6% of patients treated with focused ablation and 7.9% of the prostatectomy groups. The difference did not achieve statistical […]
PSA and Biomarker Testing Plus MRI Appears to Improve Prostate Cancer Screening
A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade cancer per 909 men, according to preliminary results from the Finnish ProScreen randomized trial. The risk difference for the group randomized to the screening […]
Some Cancer Patients Can Find It Hard to Tell Family and Friends
Ever since Anthony Bridges found out he had prostate cancer 6 years ago, he hasn’t stopped talking about it. He told his Facebook friends immediately. Now, the 68-year-old man from Georgia spends time working with others to encourage other men to talk to their doctor about getting screened. Not everyone is as eager to share, […]
Mutation Linked to Increased Risk of Prostate Cancer Mortality
The risk of dying of prostate cancer doubled in the presence of a genetic mutation affecting testosterone production, a large prospective cohort study showed. The 5-year risk of prostate cancer-specific mortality (PCSM) increased from 1.7% to as much as 4%, depending on the genotype of the HSD3B1(1245C) allele. In a subgroup of patients with metastatic […]
Study Tests Office-Based Transperineal Approach to Prostate Biopsies
A multicenter randomized trial compared transperineal prostate biopsy without antibiotic prophylaxis versus transrectal biopsy with targeted prophylaxis, examining infections, prostate cancer detection, pain, and other measures. The findings were presented at the recent Genitourinary Cancers Symposium. In this exclusive MedPage Today video, investigator Jim C. Hu, MD, of Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York […]
Improved Fitness May Reduce Prostate Cancer Risk
Improving cardiorespiratory fitness may lower men’s prostate cancer risk, results from a Swedish study suggested. The retrospective study showed that an overall increase in absolute cardiorespiratory fitness (as measured by changes in VO2max) was associated with a 2% reduced risk of prostate cancer incidence (HR 0.98, 95% CI 0.96-0.99), when adjusted for baseline fitness, age, […]
Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing
SAN FRANCISCO — A multiparametric blood test for prostate cancer showed potential to avoid more than half of unnecessary biopsies without sacrificing accuracy, a large prospective study showed. In a comparison against the current PSA testing standard of ≥4 ng/mL, the Stockholm3 biomarker, which incorporates a PSA cutoff of 15 ng/mL with other proteins and […]
Cabozantinib Plus Atezolizumab Delays Progression in mCRPC
SAN FRANCISCO — In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved radiographic progression-free survival (rPFS) versus a switch to a second hormonal agent, a phase III trial showed. The so-called CONTACT-02 study included patients with extrapelvic nodal or […]
More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effects
Men treated with androgen deprivation therapy (ADT) for prostate cancer had a significantly higher risk of dementia and other neurocognitive disorders, according to a meta-analysis of more than 2.5 million patients. The magnitude of excess risk ranged from 20% for dementia to 66% for depression. The risk of Alzheimer’s disease, vascular dementia, and Parkinson’s disease […]
Diagnostic Imaging Not Yet Enough for Biopsy-Free Radical Prostatectomy
While prostate-specific membrane antigen (PSMA)-PET may improve diagnostic accuracy in suspected prostate cancer, it may not be accurate enough to skip the biopsy when considering radical prostatectomy. In a retrospective review of 89 men with benign prostatic hyperplasia (BPH), PSMA-PET prior to biopsy had a false-positive rate of 30%, with subsequent needle biopsy revealing negative […]